Genscript Biotech (ASX: 01548) announced that its affiliate, Legend Biotech, has released initial proof-of-concept clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

The data were presented at a late-breaking session of the 2026 European Hematology Association Congress. In the ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion.

At the higher dose level, the therapy demonstrated a 100% objective response rate and an 83.3% complete response rate among evaluable patients, with all responses ongoing at the time of data analysis.

LB2501 also exhibited a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.